OLUDAMILOLA ABIDEMI OLAJIDE M.D.
Prescription History 1699730721
Internal Medicine - Hematology & Oncology in Raleigh, NC

NPI Status: Active since April 20, 2006

Contact Information

4420 LAKE BOONE TRL
SUITE 200
RALEIGH, NC
ZIP 27607
Phone: (919) 784-6818
Fax: (919) 784-6826

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for OLUDAMILOLA ABIDEMI OLAJIDE M.D., an active Hematology & Oncology specialist practicing in Raleigh, NC. Our medical registry currently tracks 21 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 924 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamoxifen Citrate, which accounts for 255 claims alone.


Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 155
30-Day Fills 388.5
Days Supply 11,636
NC State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills145.4
Peer Average Days Supply4,334
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 146.0% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,714.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.97

State Avg Cost Per Claim

$24.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 449
NC State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.5
Peer Average Days Supply435
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $97,302.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,081.38

State Avg Cost Per Claim

$15,907.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Colestipol Hcl

Generic Formulation: Colestipol HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 34.0
Days Supply 1,010
NC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills40.1
Peer Average Days Supply1,156
Conservative Utilization

This provider writes prescriptions for this formulation 44.0% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,663.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$118.81

State Avg Cost Per Claim

$100.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.

Therapeutic Applications

Colestipol is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. In addition to a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details. This medication is known as a bile acid-binding resin. It works by removing bile acid from the body. In people with high cholesterol, this causes the liver to make more bile acid by using cholesterol in the blood. This helps to lower the cholesterol levels.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 133
NC State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply449
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.97

State Avg Cost Per Claim

$16.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 76.0
Days Supply 2,264
NC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills50.3
Peer Average Days Supply1,493
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,073.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$243.91

State Avg Cost Per Claim

$232.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 56.3
Days Supply 1,690
NC State Average Benchmarks
Peer Average Claims101.0
Peer Average 30-Day Fills159.3
Peer Average Days Supply4,661
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.2% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $459.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.38

State Avg Cost Per Claim

$21.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 96.8
Days Supply 2,904
NC State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills57.7
Peer Average Days Supply1,690
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,370.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.15

State Avg Cost Per Claim

$35.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 952
NC State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply673
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 41.7% more claims than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $561,379.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,511.17

State Avg Cost Per Claim

$14,434.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
NC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply674
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,251.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$328.23

State Avg Cost Per Claim

$1,496.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
NC State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply913
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,315.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,665.07

State Avg Cost Per Claim

$14,540.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NC State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply820
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $100,250.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,113.70

State Avg Cost Per Claim

$15,844.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Kisqali

Generic Formulation: Ribociclib SuccinateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
NC State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.6
Peer Average Days Supply437
Conservative Utilization

This provider writes prescriptions for this formulation 26.7% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115,467.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,497.05

State Avg Cost Per Claim

$12,683.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ribociclib is used to treat breast cancer. It works by slowing or stopping the growth of cancer cells.

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
NC State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.3
Peer Average Days Supply505
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $265,254.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,683.65

State Avg Cost Per Claim

$14,557.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 122
30-Day Fills 254.5
Days Supply 7,618
NC State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills133.2
Peer Average Days Supply3,966
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 106.8% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,835.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.24

State Avg Cost Per Claim

$26.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 239
NC State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills69.2
Peer Average Days Supply1,512
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.0% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.97

State Avg Cost Per Claim

$26.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 43.0
Days Supply 366
NC State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.3
Peer Average Days Supply352
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.7% more claims than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $686.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.96

State Avg Cost Per Claim

$16.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 756
NC State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills50.3
Peer Average Days Supply1,363
Conservative Utilization

This provider writes prescriptions for this formulation 46.0% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $626,604.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$23,207.57

State Avg Cost Per Claim

$18,335.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 255
30-Day Fills 571.5
Days Supply 17,130
NC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills92.3
Peer Average Days Supply2,748
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 537.5% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,385.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.96

State Avg Cost Per Claim

$31.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 55.0
Days Supply 1,592
NC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply775
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.1% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,416.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.48

State Avg Cost Per Claim

$52.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 644
NC State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.8
Peer Average Days Supply490
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 35.3% more claims than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $361,284.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,708.01

State Avg Cost Per Claim

$14,339.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 31.7
Days Supply 950
NC State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills71.5
Peer Average Days Supply2,039
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.8% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,076.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,129.76

State Avg Cost Per Claim

$850.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like OLUDAMILOLA ABIDEMI OLAJIDE M.D. provides transparency into local medical care patterns within Raleigh, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.